Martingale Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Martingale Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,406	Closed	-$249K	–	838
2023 Q2	$249K	Hold	5,406	–	–	﹤0.01%	728
2023 Q1	$217K	Hold	5,406	–	–	﹤0.01%	767
2022 Q4	$250K	Hold	5,406	–	–	﹤0.01%	749
2022 Q3	$224K	Buy	5,406 +1,200	+29%	+$61.7K	﹤0.01%	763
2022 Q2	$251K	Buy	+4,206	New	+$259K	﹤0.01%	767

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Martingale Asset Management's RARE Position: Q3 2023 in Review

Martingale Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 5,406 shares — an estimated $249K sold.

Martingale Asset Management first reported a position in RARE in Q2 2022 and held it in 5 quarters. The position peaked at $251K in Q2 2022. 219 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

Martingale Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Martingale Asset Management sold 5,406 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $249K.
Martingale Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 5 quarters.
Martingale Asset Management's Ultragenyx Pharmaceutical position peaked at $251K in Q2 2022.
219 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Martingale Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.